People coming off obesity jabs like Wegovy and Mounjaro should have check-ups for at least a year to make sure they don't ...

Novo Nordisk A/V (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...

Research shows that many people regain weight after stopping treatment if they are not supported. Health chiefs have raised concerns about people regaining weight after using Wegovy and Mounjaro, ...

A WOMAN who has lost 6st using weight loss jabs has warned against one of the hidden side effects. Kelly Kay, from the UK, took to social media showing off her weight loss transformation, and ...

The National Institute for Health and Care Excellence (Nice) issues advice as 1.5 million Brits are using weight loss ...

Demand for weight-loss and diabetes drugs seen global surge, CEO says move will come once patents begin to expire next year ...

Health chiefs have raised concerns about patients regaining weight after stopping popular weight-loss drugs such as Wegovy and Mounjaro, calling for robust support to prevent them from piling on the ...

Experts say NHS patients should be monitored for at least a year after treatment ends, with tailored support provided if ...

People coming off obesity jabs like Wegovy and Mounjaro should have check-ups for at least a year to make sure they don't ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success ...